Subhadip Kundu
Research Subjects
Subhadip Kundu has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Aaron Morawski
NextCure Inc., Beltsville, Maryland, USA
1 shared publication- Agnieszka E. Gorska
Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
1 shared publication - Ana Paucarmayta
Department of Obstetrics & Gynecology, Uniformed Services University, 4301 Jones Bridge Road, Bethesda, MD 20814, USA
1 shared publication - Carly M. Fielder
Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA
1 shared publication - Dallas B. Flies
NextCure Inc , Beltsville, MD
1 shared publication - Emilia A. Barbu
NextCure Inc., Beltsville, Maryland, USA
1 shared publication
Latest Publications
- Open Access
- 15 November 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (22)
LAIR-1 agonism as a therapy for acute myeloid leukemia
Effective eradication of leukemic stem cells (LSCs) remains the greatest challenge in treating acute myeloid leukemia (AML). The immune receptor LAIR-1 has been shown to regulate LSC survival; however, the therapeutic potential of this pathway remains unexplored. We developed a therapeutic LAIR-1 agonist antibody, NC525, that induced cell death of LSCs, but not healthy hematopoietic stem cells in vitro, and killed LSCs and AML blasts in both cell- and patient-derived xenograft models. We showed that LAIR-1 agonism drives a unique apoptotic signaling program in leukemic cells that was enhanced in the presence of collagen. NC525 also significantly improved the activity of azacitidine and venetoclax to establish LAIR-1 targeting as a therapeutic strategy for AML that may synergize with standard-of-care therapies.
- 15 November 2023
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (22)
Open AccessLAIR-1 agonism as a therapy for acute myeloid leukemia
Effective eradication of leukemic stem cells (LSCs) remains the greatest challenge in treating acute myeloid leukemia (AML). The immune receptor LAIR-1 has been shown to regulate LSC survival; however, the therapeutic potential of this pathway remains unexplored. We developed a therapeutic LAIR-1 agonist antibody, NC525, that induced cell death of LSCs, but not healthy hematopoietic stem cells in vitro, and killed LSCs and AML blasts in both cell- and patient-derived xenograft models. We showed that LAIR-1 agonism drives a unique apoptotic signaling program in leukemic cells that was enhanced in the presence of collagen. NC525 also significantly improved the activity of azacitidine and venetoclax to establish LAIR-1 targeting as a therapeutic strategy for AML that may synergize with standard-of-care therapies.